Arlene O. Siefker-Radtke, MD
Disclosures: Membership on advisory committees or review panels, board membership, etc.-AstraZeneca-|Membership on advisory committees or review panels, board membership, etc.-Basilea Pharmaceutical LTD-|Paid consultant-Bavarian Nordic-|Paid consultant-Genentech, Inc.-|Paid consultant-Janssen-|Membership on advisory committees or review panels, board membership, etc.-Janssen-|Paid consultant-Merck Sharp & Dohme Corp-|Membership on advisory committees or review panels, board membership, etc.-Mirati Therapeutics-|Membership on advisory committees or review panels, board membership, etc.-Seattle Genetics, Inc.-|Paid consultant-Taiho Pharmaceutical Company, Inc.-|Paid consultant-Bristol-Myers Squibb-|Paid consultant-Immunomedics-|Membership on advisory committees or review panels, board membership, etc.-Ideaya Biosciences-|Grant or research support-Basilea Pharmaceutical LTD-|Grant or research support-Bristol-Myers Squibb-|Grant or research support-Merck-|Grant or research support-Nektar-|Grant or research support-Janssen- - 04/16/2021

             

  Arlene Siefker-Radtke, M.D.                           

     Professor

 

 

 

Arlene Siefker-Radtke is a Professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center. Her research focus is on developing effective therapies in the treatment of urothelial cancer and other rare tumors of the bladder and upper tract. She is well-known for her novel clinical trial designs, development of novel agents and targets including immunotherapy and cytokine analogues, FGFR inhibitors, development of neoadjuvant chemotherapy, and expertise in treating even those most rare tumors of the bladder.

 

http://mdabrandcentral.com/mdautbf/MDA_Logos/MDACC_MasterBrand_Logos/2-color/previews/MDACC_2C_RGB_TC_tag_V-zm.gif

Department of Genitourinary Medical Oncology Division of Cancer Medicine